Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The SARS-CoV-2 Vaccine Response and Safety in Rheumatology Patients and the Influence of Temporary Interruptions in Immunomodulatory Therapy

NCT05080218 is registered in ClinicalTrials.gov with Jeffrey Curtis as lead sponsor.

NCT NCT05080218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05080218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The SARS-CoV-2 Vaccine Response and Safety in Rheumatology Patients and the Influence of Temporary Interruptions in Immunomodulatory Therapy
Lead sponsor
Jeffrey Curtis
Phase
Phase 4
Overall status
Completed
Start date
November 15, 2021
Completion date
May 28, 2024
Enrollment
841 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis, rheumatoid arthritis, spondylarthritis